This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine

Ariad Pharmaceuticals (ARIA) CEO Harvey Berger, sounding defiant, even angry at times, convened a marathon conference call Thursday to refute concerns about the safety and early commercial launch of the company's leukemia drug Iclusig.

Berger took special aim at Ariad critic Favus Institutional Research, calling a negative report on Iclusig released Wednesday, "incomplete and replete with misinformation, innuendo and false conclusions."

Through the first 12 weeks of its U.S. commercial launch, "more than" 325 chronic myeloid leukemia (CLM) patients are paying for Iclusig treatment, with additional, undisclosed number of patients receiving some free drug, Ariad said.

The new disclosure led investors and analysts on the call scurrying to their Excel spreadsheets, trying to estimate first quarter sales. Ariad could have made it easy on everyone by simply pre-announcing Iclusig sales but the company chose not to.

Analyst consensus for first-quarter Iclusig sales was $4 million prior to Thursday's call, although the "whisper number" based on existing prescription data is more like $5-6 million.

I spoke with one institutional investor with no position in Ariad who now estimates Iclusig sales for the quarter will be $3.5 million to $5 million, depending on the conversion rate of patients from free drug to paid prescriptions.

"If you're really bullish on Iclusig, why not pre-announce first-quarter Iclusig sales?" asks another investor who is short Ariad and isn't covering following Thursday's call. "What I heard on the call was 90 minutes of Harvey babbling and contradicting himself."

On his call, Berger insisted Iclusig is well received by doctors and patients and that concerns about the drug's toxicity were overblown. The rate and type of side effects being reported are not different from what was seen in clinical trials or what's contained in the drug's FDA-approved label, he said.

Iclusig's label includes a black box warning against blood clots causing fatal heart attacks and strokes, and liver toxicity including liver failure and death.

The Favus research note negative on Iclusig published Wednesday refers to a survey of doctors treating CML patients with the drug who are finding it to be more toxic and less tolerable than expected. "Iclusig has a very small role to play in heavily pre-treated CML patients with the T315I mutation (extremely rare); as time goes on, that observation is becoming obvious," the Favus note said.

Ariad insists Iclusig will be used broadly in all types of CML patients. The company is conducting a study comparing Iclusig to Novartis' (NVS) Gleevec in newly diagnosted CML patients.

Ariad shares rose 3% to $17.27 in early Thursday trading, which is still down from $22 in mid-March . The bull-bear fight over Iclusig seems far from over.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs